Iterum Therapeutics (NASDAQ:ITRM) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Iterum Therapeutics (NASDAQ:ITRM) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports.

According to Zacks, “Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company’s product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. “

Several other research analysts have also recently commented on ITRM. Royal Bank of Canada boosted their price target on shares of WestJet Airlines from C$20.00 to C$31.00 and gave the stock a sector perform rating in a report on Wednesday, May 15th. Needham & Company LLC reiterated a buy rating and set a $20.00 price target on shares of Iterum Therapeutics in a report on Monday, March 25th. Finally, HC Wainwright reiterated a buy rating on shares of Interpace Diagnostics Group in a report on Friday, June 21st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $15.75.



NASDAQ ITRM opened at $6.68 on Wednesday. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.24. Iterum Therapeutics has a 52 week low of $4.70 and a 52 week high of $11.22. The firm has a market cap of $93.25 million, a PE ratio of -0.94 and a beta of 2.05. The business’s 50 day moving average price is $6.70.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.09). Iterum Therapeutics had a negative return on equity of 83.95% and a negative net margin of 11,956.64%. The firm had revenue of $0.04 million for the quarter. Sell-side analysts predict that Iterum Therapeutics will post -6.43 earnings per share for the current year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Further Reading: How does the Beige Book influence monetary policy?

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.